Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Trastuzumab F(ab')2.
Recognizes Trastuzumab specifically, no cross reactivity with other humanized antibodies.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 years under sterile conditions after reconstitution.
Anti-Trastuzumab Antibodies on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Anti-Trastuzumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized trastuzumab at 1 µg/mL, add increasing concentrations of Anti-Trastuzumab Antibodies (Cat. No. TRB-Y7, 10% human serum) and then add biotinylated trastuzumab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 19 ng/mL.
Demonstration of the specificity of Anti-Trastuzumab Antibodies (Cat. No. TRB-Y7) to the trastuzumab.
Measured by its neutralizing ability in a functional ELISA. Immobilized trastuzumab at 0.5 μg/mL (100 μL/well) can bind pre-mixed Anti-Trastuzumab Antibodies (Cat. No. TRB-Y7) and Biotinylated Human HER2 (Cat. No. HE2-H82E2) with a inhibition rate of 89%.
Anti-Trastuzumab Antibodies bridging MSD for Anti-Drug Antibody (ADA) assay development. Added the mix solution (biotinylated Trastuzumab at 5 µg/mL, SULFO-Trastuzumab at 5 µg/mL and increasing concentrations of Anti-Trastuzumab Antibodies (Cat. No. TRB-Y7, 100% human serum). Detection was performed using MSD Assay with a sensitivity of 3.9 ng/mL.
Anti-Trastuzumab Antibodies (mouse IgG1, Cat. No. TRB-Y7) captured on CM5 chip via anti-mouse antibodies surface, can bind human trastuzumab with an affinity constant of 0.452 nM.
Trastuzumab, is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive. Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication. Trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein.